Back to announcement
20240912_SCPI_Tanggapan atas Permintaan Penjelasan Bursa_31725589_lamp2.pdf
Other Text extracted SCPISource file signed link, expires in 15 minutes
Extracted text 4
Page 1
Sinarmas MSIG Tower 37th floor unit 102-106
Jl. Jend. Sudirman Kav 21
Karet, Setiabudi, Jakarta Selatan,
DKI Jakarta 12920
Phone No (62) 21-31107000
Fax No (62) 21-31107009
No. 099/OPI/IX/2024 Jakarta, 12 September 2024
Kepada Yth./ To:
Bursa Efek Indonesia / Indonesia Stock Exchange (“BEI”)
Indonesia Stock Exchange Building,
Tower I, 6th Floor,
Jl. Jend. Sudirman Kav.52-53, Jakarta 12190 – Indonesia
U.p./Attn: Kepala Divisi Penilaian Perusahaan 3 / Head of Company Assessment Division 3
Perihal: Penyampaian Tanggapan atas Surat Subject: Response Submission to BEI’s Letter
BEI sehubungan dengan Permintaan concerning Request for Explanation of PT
Penjelasan PT Organon Pharma Indonesia Tbk Organon Pharma Indonesia Tbk
Dengan hormat, Dear Sir/Madam,
Merujuk surat BEI No. S-09297/BEI.PP3/09-2024 Referring to BEI’s letter No. S-09297/BEI.PP3/09-
tanggal 3 September 2024 tentang Permintaan 2024 dated 3 September 2024 regarding Request
Penjelasan PT Organon Pharma Indonesia Tbk for Explanation of PT Organon Pharma Indonesia
(“Surat BEI”) yang ditujukan kepada PT Organon Tbk (“BEI’s Letter”) addressed to PT Organon
Pharma Indonesia Tbk (“Perseroan”), bersama Pharma Indonesia Tbk (“Company”), with this
dengan surat ini Perseroan bermaksud untuk letter the Company intends to submit the
memberikan beberapa tanggapan atas Surat BEI explanation to the pertaining BEI’s letter.
tersebut.
Adapun yang dapat kami berikan klarifikasi saat ini At this point of time, Company will give clarification
: for;
1. Kondisi Perseroan Saat Ini 1. Company Current Situation
a. Saat ini Perseroan mengelola dua a. At this point of time, The Company
segmen, yaitu manufaktur dan produk manages 2 business segments,
komersial. namely manufacturing and
i. Manufaktur : Segmen manufaktur commercial pharmaceutical products.
saat ini sebagai kontributor utama i. Manufactur : Currently manufactur
Perseroan. segment is a main contributor for
ii. Komersial : Segmen komersial the Company
sebagai pendukung bagi Perseroan ii. Commercial : Commercial segment
is a proponent for a Company
b. Kapasitas Produksi b. Production Capacity
c. Fokus dan Strategi Perseroan saat ini c. Focus and Company Strategic
Page 2
Sinarmas MSIG Tower 37th floor unit 102-106
Jl. Jend. Sudirman Kav 21
Karet, Setiabudi, Jakarta Selatan,
DKI Jakarta 12920
Phone No (62) 21-31107000
Fax No (62) 21-31107009
i. Menyerap permintaan yang i. Absorb increasing demand without
meningkat, tanpa ada masalah pada any supply problems, through
pasokan. Melalui optimasi optimizing raw material supplies
persediaan bahan baku ii. Cost efficiency through process
ii. Efisiensi biaya melalui optimasi dan optimization and systematization,
sistematisasi proses serta while also increasing the number of
peningkatan jumlah spesialis QA. QA specialists
iii. Peningkatan akurasi dan efisiensi iii. Increased accuracy and efficiency of
proses ekspor impor the import export process
iv. Simplifikasi proses pelaporan data iv. Simplification of the data reporting
yang berhilir pada kepatuhan process, leading to better and faster
terhadap peraturan yang lebih baik regulatory compliance
dan cepat
d. Strategi pengembangan yang akan d. Development strategy that will be
dilakukan Perseroan carried out by the Company
i. Perseroan berkomitmen untuk i. The Company committed to ensure
memastikan strategi perusahaan the current strategy is well
saat ini dilakukan dengan baik implemented.
2. Kondisi Keuangan dan Penyajian Laporan 2. Financial Condition and Submission of
Keuangan Financial Reports
a. Informasi mengenai tiga komponen a. Information of three main components
utama atas aset lancar dan masing- on current assets and balance as of
masing saldo per 30 Juni 2024 Jun, 30th 2024
Keterangan Jumlah Keterangan Jumlah
Prepaid Exp - Exposed - FX 614,032,565 Prepaid Exp - Exposed - FX 614,032,565
Prepaid Exp - Insurance - General 3,094,974,885 Prepaid Exp - Insurance - General 3,094,974,885
b. Informasi mengenai rincian per b. Information regarding details per
pemasok atas uang muka perolehan supplier of advances for the acquisition
aset tetap per 30 Juni 2024 beserta of fixed assets as of 30 June 2024
jenis aset tetap yang akan dibeli along with the types of fixed assets to
be purchased
Keterangan Jumlah Keterangan Jumlah
Down Payment Pembelian Mesin 11,755,655,109 Down Payment Pembelian Mesin 11,755,655,109
Down Payment Pembelian Alat Lab 430,125,000 Down Payment Pembelian Alat Lab 430,125,000
c. Sehubungan dengan aset hak guna c. In connection with the Company's
Perseroan right-of-use assets
i. Transaksi yang menyebabkan i. Transactions that cause the
timbulnya aset hak guna Company's right-to-use assets
Perseroan – Sewa Gedung to arise – building rent
d. Sehubungan dengan CALK 6 tentang d. In connection with CALK 6, regarding
piutang usaha the trade receivables
i. Memonitor status piutang i. Periodically monitoring the
secara berkala receivable account
ii. Melakukan follow up atas ii. Follow up for the due
piutang yang sudah jatuh receivable account
tempo
Page 3
Sinarmas MSIG Tower 37th floor unit 102-106
Jl. Jend. Sudirman Kav 21
Karet, Setiabudi, Jakarta Selatan,
DKI Jakarta 12920
Phone No (62) 21-31107000
Fax No (62) 21-31107009
e. Transaksi yang menyebabkan e. Transactions that cause other
timbulnya piutang lain-lain receivables to arise
i. Pengembalian dan jasa i. Reimbursement and
management management fee
ii. Jangka waktu piutang 90 hari ii. The receivable term is 90 days
dan bunga 1% per bulan atas and interest is 1% per month on
saldo terhutang the outstanding balance
f. Sehubungan dengan CALK 7 tentang f. In Connection with CALK 7 regarding
persediaan supply
i. Informasi mengenai strategi i. Information of management
manajemen persediaan strategy for Company supply -
Perseroan – Managemen Management registered
mendaftarkan asuransi insurance against earthquake
terhadap risiko gempa bumi risks and other risks on 31 Dec
dan risiko lainnya pada 31 Dec 2023 and 30 June 2024. Apart
2023 dan 30 Juni 2024. Selain from that, none of the inventory
itu persediaan yang dimiliki owned by the Company is used
Perseroan tidak ada yang as collateral
dijadikan jaminan. ii. Justification background – please
ii. Latar belakang justifikasi – refer to page 32 of Q2 financial
mengacu pada hal 32 laporan statement
keuangan Q2 2024 iii. Types of inventory experiencing
iii. Jenis persediaan yang impairment along with details of
mengalami penurunan nilai their value – some slow moving
beserta rincian nilainya – products relate to contraceptive
beberapa product slow moving products, the company is not sure
berkaitan dengan produk the product will be sold
kontrasepsi, perusahaan tidak iv. Current condition of inventory
yakin produk akan terjual which has experienced a decline
iv. Kondisi terkini atas persediaan in value - the Company will carry
yang mengalami penurunan out destruction
nilai tersebut – Perseroan
akan melakukan pemusnahan
Demikian tanggapan yang dapat kami sampaikan. Thus we convey this clarification. Thank you for
Atas perhatiannya, kami mengucapkan terima your kind attention.
kasih.
Page 4
Sinarmas MSIG Tower 37th floor unit 102-106
Jl. Jend. Sudirman Kav 21
Karet, Setiabudi, Jakarta Selatan,
DKI Jakarta 12920
Phone No (62) 21-31107000
Fax No (62) 21-31107009
Hormat Kami/Best Regards
PT Organon Pharma Indonesia Tbk
Nama/Name: Daniel
Jabatan/Title: President Director
Names mentioned 7 people and organisations named in the text · linked when the evidence is strong
unresolved
org
Indonesia Stock Exchange
p.1 ×2
unresolved
org
Pharma Indonesia Tbk
p.1
unresolved
person
Nama/Name: Daniel
· Jabatan/Title: President Director
p.4
Extraction attempts how the parser did, and what it refused
Nothing structured was extracted from this document — the attempts below say why.
No extraction attempted yet.